Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
24 juin 2021 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Study did not meet primary endpoint of Total Improvement Score (TIS) at Week 28Additional findings included nominally significant improvements in TIS (p = 0.0302) and CDASI (p = 0.0166) depending on...
Corbus Pharmaceuticals Reports Last Subject Visit in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
30 mars 2021 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Topline data on schedule for Q2 2021Dermatomyositis is a rare and life-threatening autoimmune disease characterized by skin and muscle inflammation, and affects ~80,000 people in North America, EU,...
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Financial Results
15 mars 2021 07h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
●Phase 3 study of lenabasum in dermatomyositis on schedule for topline data in Q2 2021 ●Company focused on advancing in-house programs in metabolic diseases, fibrotic disorders, and cancer with...
Corbus Pharmaceuticals Completes Enrollment in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
05 août 2020 09h25 HE
|
Corbus Pharmaceuticals Holdings, Inc.
12-month, double-blind, placebo-controlled, multi-national study enrolled 176 participantsTopline results expected in fourth quarter of 2021 Dermatomyositis is a rare, systemic autoimmune disease with...
Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis
22 juin 2020 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Topline data on schedule for Q3 2020Reduction in pulmonary exacerbations (PEx) as primary endpoint Study enrolled 426 participants regardless of CFTR mutation or background CFTR-targeting...
Corbus Pharmaceuticals Reports 2019 Third Quarter Financial Results and Provides Clinical and Corporate Updates
07 nov. 2019 07h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Phase 3 “RESOLVE-1” study of lenabasum for treatment of systemic sclerosis on track for topline results in summer of 2020Systemic sclerosis is a rare autoimmune disease affecting ~200,000 people in...
Corbus Pharmaceuticals to Host 2019 R&D Day in New York City
17 juin 2019 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
- R&D Day to be live video webcasted on Friday, June 21st at 10:00 AM ET - Norwood, MA, June 17, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the...
Lenabasum Open-Label Extension Data to be Presented at EULAR 2019 Continue to Show a Favorable Safety Profile and Improvement in Efficacy Outcomes in Systemic Sclerosis and Dermatomyositis Phase 2 Studies
12 juin 2019 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
ACR CRISS score remains ≥ 0.95 (95%) at 21 months in systemic sclerosis open-label extension (OLE) studyCDASI activity score reaches -21.8 points at 16 months in dermatomyositis OLE study81% systemic...
Corbus Pharmaceuticals Announces Strategic Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Lenabasum in Japan for Systemic Sclerosis and Dermatomyositis
03 janv. 2019 10h01 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Collaboration in-line with Corbus vision to become the global leader in the treatment of inflammatory and fibrotic diseases by targeting the endocannabinoid systemAdvances strategy to partner...
Corbus Pharmaceuticals Announces Issuance of Composition of Matter Patent Related to Lenabasum
18 déc. 2018 08h46 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Company’s vision is to become the leader in the treatment of inflammatory and fibrotic diseases by targeting the endocannabinoid systemLenabasum in late-stage clinical studies in three orphan...